Inhibitory effect of adenovirus mediated VEGF-siRNA on transplanted osteosarcoma in nude mice

Chinese Journal of Cancer Biotherapy

Volumn 15, Issue 3, 2008, Pages 243-247

  Gao, You Shui ^a   Mei, Jiong ^a   Tong, Tian Lang ^a   Hu, Mu ^a   Xue, Hua Ming ^a   Cai, Xuan Song ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Adenovirus; Antiangiogenic therapy; Gene therapy; Osteosarcoma; RNA interference (RNAi); Vascular endothelial growth factor (VEGF)

Indexed keywords

ADENOVIRUS VECTOR; SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 77953376050     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285 (21): 1182-1186.
2. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics [J]. J Glin Oncol, 2001, 19 (4): 1195-1206.
3. Folkman J. Angiogenesis[J]. Annu Rev Med, 2006, 57: 1-18.
4. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art[J]. Cancer Treat Rev, 2006, 32(6): 423-436.
5. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma[J]. Cancer, 2007, 109(5): 813-819.
6. Weiss KR, Cooper GM, Jadlowiec JA, et al. VEGF and BMP expression in mouse osteosarcoma cells[J]. Clin Orthop Relat Res, 2006, 450: 111-117.
7. Chinese source.
8. Charity RM, Foukas AF, Deshmukh NS, et al. Vascular endothelial growth factor expression in osteosarcoma [J]. Clin Orthop Relat Res, 2006, 448: 193-198.
9. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: an analysis within a group of patients, all of whom developed lung metastasis[J]. Mod Pathol, 2006, 19 (5): 738-745.
10. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma [J]. Europ J Cancer, 1999, 35 (7): 1089-1093.
11. Jüllig M, Zhang WV, Stott NS. Gene therapy in orthopaedic surgery: the current status [J]. ANZ J Surg, 2004, 74 (1-2): 46-54.
12. Witlox MA, Lamfers ML, Wuisman PI, et al. Evolving gene therapy approaches for osteosarcoma using viral vectors: review [J]. Bone, 2007, 40 (4): 797-812.
13. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans [J]. Nature, 1998, 391 (6669): 806-811.
14. Chinese source.
15. Shen HL, Xu W, Wu ZY, et al. Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF) 165 expression in human leukemia cells[J]. Leuk Res, 2007, 31 (4): 515-521.
16. Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics [J]. Cancer Res, 2004, 64 (10): 3365-3370.
17. Filleur S, Courtin A, Ait-Si-Ali S, et al. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vacularization and growth [J]. Cancer Res, 2003, 63 (14): 3919-3922.
18. Ternovoi VV, Curiel DT, Smith BF, et al. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma [J]. Lab Invest, 2006, 86 (8): 748-766.
19. Chinese source.